Negative Feedback Regulation following Administration of Chronic Exogenous Corticosterone by Young, Elizabeth A. et al.
Journal of Neuroendocrinology, 1995. Vol. 7. 37-45 
Negative Feedback Regulation following Administration of Chronic 
Exogenous Corticosterone 
Elizabeth A. Young, Seung P. Kwak and Juliet Kottak 
Mental Health Research Institute and Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, USA. 
Abstract 
Administration of exogenous glucocorticoids is known to suppress the HPA axis and has been reported to occupy brain glucocorticoid 
receptors, eventually leading to down-regulation. To determine the effects of chronic corticosterone administration on HPA axis function, 
corticosterone was administered as both 25% and 50% corticosteronekholesterol pellets. Rats were sacrificed 6 days after corticosterone 
pellet implantation. The 25% corticosterone pellets produced a small increase in morning corticosterone concentrations but no change 
in evening ACTH or corticosterone secretion. The 50% corticosterone pellets produced constant corticosterone concentrations of 
5-6 pg/dl, with no circadian variation in corticosterone, indicating inhibition of evening ACTH and corticosterone secretion. The 25% 
corticosterone pellets produced no significant decrease in thymus weight or in adrenal weight; 50% corticosterone pellets produced 
significant decreases in thymus weight and adrenal weight. Neither 25% nor 50% corticosterone pellets produced significant decreases 
in GR in hippocampus and cortex. The 50% corticosterone pellets treatment resulted in a decrease in anterior pituitary POMC mRNA 
levels, a decrease in baseline and oCRH stimulated ACTH release from the anterior pituitary, and a near complete inhibition of the AM 
and PM response to restraint stress. These results suggest that: 1) the HPA axis was able to adjust to the small increase in glucocorticoids 
produced by the 25% cort pellets with minimal disturbances in function and 2) 50% corticosterone pellets exert a significant inhibitory 
effect on stress and diurnal ACTH secretion which appears to be exerted at the pituitary as well as possible inhibitory effects on brain. 
Glucocorticoid secretion is tightly controlled by an elaborate 
systems of checks and balances. In particular, the circulating 
concentrations of glucocorticoid ‘feedback’ to the controlling 
elements at multiple levels to turn off glucocorticoid secretion 
and consequently maintain the right range of glucocorticoids ( 1, 
2 ) .  In man, administration of exogenous glucocorticoids clearly 
suppresses endogenous glucocorticoid secretion, resulting in 
adrenal atrophy with prolonged administration (3). Although 
exogenous glucocorticoids suppress cortisol or corticosterone and 
ACTH secretion, whether the site of feedback inhibition is 
the brain or pituitary is less clear. Dexamethasone, a synthetic 
glucocorticoid commonly used to monitor the ‘normality’ of the 
feedback circuits, appears to exhibit particularly profound inhibit- 
ory effects on the pituitary corticotrophs, and most data suggest 
that its primary site of negative feedback action is the pituitary 
(4, 5. 6). 
Circadian variation of corticosterone secretion is the normal 
pattern in a number of species including rat and man. The 
circulating levels of glucocorticoids show a circadian rhythm with 
peak and trough levels varying an order of magnitude (3, 7, 8, 
9). The circadian variation in cortisol secretion is believed to 
reflect the circadian pattern of corticotropin releasing factor 
(CRF 1 from the paraventricular nucleus. Patients suffering from 
Cushing’s disease, an ACTH secreting corticotroph tumor, gener- 
ally demonstrate an absence of a circadian rhythm in ACTH or 
cortisol secretion, presumably because the tumor secretion is 
independent of CRH input and the high concentration of circulat- 
ing glucocorticoids inhibit the neural elements responsible for 
CRH secretion which drives the circadian rhythm of cortisol. (3) 
In contrast, patients suffering from depression, a disorder that 
stimulates HPA axis activation through neural pathways, often 
demonstrate hypercortisolemia with elevated plasma glucocort- 
icoid secretion at both the zenith and nadir of the circadian 
rhythm (10-14). Whether these two different patterns of gluco- 
corticoid secretion exert different effects on brain is not known. 
Although brain glucocorticoid receptors (GR) are traditionally 
measured following adrenalectomy, the number of cytosolic GR 
can also be measured in non-adrenalectomized rats. When meas- 
ured in intact rats this number of cytosolic receptors in hippocam- 
pus and cortex reflects the number of non-translocated receptors 
and can be used to determine the effects of in vivo manipulations 
such as acute stress, acute glucocorticoid administration or diurnal 
changes over the circadian rhythm (15, 16, 17, 18). Elegant 
studies by Miller et al. have characterized this method as a means 
of determining receptor occupation following administration of 
dexamethasone and corticosterone ( 17). Consequently, measure- 
ment of GR in adrenally intact rats may be useful as an index of 
glucocorticoid receptor occupation and provide information on 
whether a feedback signal is being exerted primarily at the brain. 
The following studies were undertaken to compare the effects of 
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different doses glucocorticoids administered as a continuous 
corticosterone pellet on neural and peripheral elements of the 
HPA axis, including receptor activation. Corticosterone was 
chosen as the glucocorticoid to be administered since it has high 
aflinity for both mineralocorticoid receptors ( M R )  and glucocort- 
icoid receptors ( G R )  in the brain, in contrast to  the synthetic 
ligand dexamethasone which binds poorly to MR. Previous 
studies by us and others had characterized the effects of the 
continuous release pellets used as replacement doses in adrenalec- 
tomized rats on plasma ACTH and corticosterone. and glucocort- 
icoid and mineralocorticoid binding ( 2 .  19, 20). However, the 
plasma corticosterone levels achieved and the pattern of adapta- 
tion arc likely to be different in adrenally intact animals from 
that shown in adrenalectomized animals. Consequently, the cur- 
rent studies were undertaken to explore how the HPA axis as a 
system adapts to an increase in glucocorticoids administered as a 
slow release corticosterone pellet, and a t  what levels of the HPA 
axis the feedback signal may be active. 
Results 
T~vc~rzt~v-firr pe  cent pellet esperiments 
The effect of implantation of 25% corticosterone pellets were 




corticosterone levels were low in the a.m. of the cholesterol pellet 
rats ( 1.55 f0.6 pg/dl) and very slightly increased in the corticos- 
terone pellet rats (3.4f0.8 pg/dl). The plasma corticosterone 
levels in the p.m. were identical in the two groups (12.7 ,ug/dI in 
both groups). Plasma ACTH and corticosterone data are shown 
in Figure 1. There was a significant a.m./p.m. difference in plasma 
ACTH, but no effect of corticosterone pellet treatment on plasma 
ACTH. Neither adrenal weight nor thymus weight, a sensitive 
index of integrated glucocorticoid concentrations in the periphery, 
was significant decreased in the rats receiving 25% corticosterone 
pellets. There were no differences in body weight between choles- 
terol and corticosterone pellet rats. Pituitary ACTH content and 
POMC mRNA levels were unchanged by 25°/;! corticosterone 
pellet treatment. There were no significant effects of 25% corticos- 
terone pellets on G R  in hippocampus, cortex or hypothalamus 
(Table 1 ). The K,s from Scatchard analysis were very similar for 
both groups in the cortex and hippocampus (2.2 & 0.2 nM for 
sham and 2.4f0.3 n M  cort in the cortex and 3.3k 1.3 nM 
for sham and 2.6k0.7 nM in the hippocampus). There were no 
detectable mineralocorticoid receptors in any brain region from 
either group of rats. 
Fifty per cent corticosterone pellets 
Implantation of 50% corticosterone pellets resulted in very differ- 
ent hormonal profiles than 25% pellets. The data are shown in 
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FIG. I .  Comparison of plasma corticosterone (panel A)  and plasma ACTH (panel B) in the morning (a.m.) and evening (p.m.) in sham and 25"'n 
corticosterone treated rats 6 days following implantation of these pellets. The 25% cort pellet treated rats show a small increase in cort in the a.m. 
(panel A), which is accompanied by a small decrease in plasma ACTH (panel B )  at the same time. No change in plasma corticosterone or ACTH is 
sccn in the p.m. in the cort treated rats. a.m.; p.m.. 
TABLE 1. Comparison of 25'%1 and 50% Corticosterone Treated Rats and their Respective Sham Treated Controls on HPA Axis and 
Brain GR Binding Measures. 
25')C1 Control 25'!'0 Cort Pellet 50% Control 50'14) Cort Pellet 
Anterior pit ACTH. pmoles'pit 325 & 60 308 f 32 269 + 35 231 +34 
POMC mRNA (OD) 116+27 121 k21 109k11 80+11* 
Adrenal weight mg 35.4 f 2 31.1 k2.1 33.8k2.1 22.6 +2.3* 
Thymus weight mg 590+31 508 & 40 481+22 351 +20* 
Mean cortex GR fnioles/mg protein + 166f25 146k 11  155&26 14Ofl4.J  
Mean hippocampus GR fmoles mg protein+ 110+16 104f18 85.2+ 14 84.6 20.6 
Mean hypothalamus GR fmoles/mg protein + 68.7k5.1 11.3 f 8.3 58.4k8.8 49.4 + 8 
*=significantly diferent from the matched controls by ANOVA (50"4, cort. experiment); + =Mean of both a.m. and p.m. values, n =  12 per group 
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pellets and were sacrificed in the morning of day 6. This 
experiment used a two-by two design, with half the rats receiving 
corticosterone pellets and the other half inactive cholesterol 
pellets and half of each group of rats received dexamethasone in 
the drinking water. Consequently, it is possible to compare each 
glucocorticoid treatment as well as examine the additive effects 
of both treatments. In this experiment, CRH mRNA in the 
PVN and GR and MR mRNAs in the hippocampus were also 
measured. Again, a.m. plasma corticosterone was increased 
in the corticosterone treated animal to 6.8 & 1.4. Significant 
decreases in plasma ACTH (P=0.05) and thymus weight 
(P=O.OOl) were observed in both 50%) corticosterone pellet 
treated and in acute dexamethasone treated rats. Receptor 
binding studies again demonstrated no significant decrease in 
GR number in hippocampus or cortex in 50%) corticosterone 
treated rats, but a significant decrease was observed in rats given 
dexamethasone in their drinking water (cort Rx F = 0.4. df = 1 ,  
p=n.s.; dex Rx F=15, d f = l ,  P=0.0004). A similar decrease 
was seen in both cortex and hippocampus (3-Way ANOVA, no 
significant difference between brain region). Neither corticos- 
terone pellet treatment nor acute dex treatments affected GR or 
MR mRNA in hippocampus (Table 2) .  There was no significant 
effect of corticosterone pellet treatment on CRH mRNA in the 
PVN, but there was a significant effect of dex treatment (Table 2, 
Cort Rx F=0.9, d f= l .  p=ns; dex Rx F=9.3, P=O.O07). The 
pituitaries from these rats were processed into single cell 
suspensions and then challenged with 1 nM ovine corticotrophin 
releasing factor (oCRF). The pituitaries from 3 rats were pooled 
for these challenge studies. A total of 6 animals per group was 
examined and data are the means of both pools. Anterior 
pituitary cell preparations from the 4 groups of rats were 
challenged with 1 nM oCRH. The data are shown in Fig. 3. 
Chronic corticosterone pellets reduced the baseline and oCRH 
stimulated ACTH secretion, but the responsiveness to oCRH, 
expressed as per cent unstimulated baseline is the same in both 
groups (150%). Acute dex treatment and the combination of 
acute dex plus cort pellets produced decreases in both ACTH 
Fig. 2, panel A. By day 6, the 50% pellet rats clearly demonstrate 
an inhibition of the normal p.m. rise in corticosterone, suggesting 
a flat circadian rhythm of corticosterone, while cholesterol pellet 
controls demonstrate a normal circadian rhythm of corticos- 
terone. The plasma ACTH data also demonstrated a clear circa- 
dian rhythm of ACTH in the rats treated with cholesterol pellets. 
(Fig. 2 panel B, F=9.1, df= 1, P=0.0074). Six days following 
pellet implantation, there was a significant effect of 50% corticos- 
terone pellets on plasma ACTH ( F= 17, df=  1, P=0.0006). The 
corticosterone pellet treatment was able to completely block the 
p.m. rise in ACTH (significant interaction of treatment and time 
of day, F = 9.8, P = 0.0057 ). Peripheral indices of integrated 
corticosterone secretion, thymus weight and adrenal weight, were 
significantly decreased in the 50% corticosterone pellet treated 
rats (thymus weight, ANOVA F=16.5, df=1. P=O.O002 for 
corticosterone treatment; adrenal weight ANOVA F = 82.6, 
df= 1, P = 0.0001 for corticosterone treatment). Anterior pituitary 
ACTH content was not significantly decreased, although proopi- 
omelanocortin ( POMC ) mRNA levels were significantly 
decreased in corticosterone treated rats (ANOVA, corticosterone 
F =  10.7, df= 1,  P=0.0025; no a.m. versus p.m. differences and 
no significant interaction). Brain glucocorticoid receptors (GR)  
were assayed in the hippocampus, cortex and hypothalamus, to 
determine if glucocorticoid pellets were able to lead to significant 
occupation of cytosolic GR. Despite this clear indication of 
increased mean glucocorticoid concentrations in corticosterone 
pellet rats, there was no decrease in cytosolic GR in any regions 
of brain. Even in the a.m., when corticosterone concentrations 
were significantly elevated in the 50%) corticosterone pellet rats 
compared to cholesterol treated rats, no significant decrease in 
GR was observed. No differences in Kd were seen between 
control and corticosterone treated rats (Cortex = 0.13 nM for each 
group, Hippocampus = 1 .O nM for each group: Bmax =Cortex 
176 vs 168: Bmax Hippocampus 176 vs 171). Again, in none of 
the regions was an MR binding signal detectable in either 
cholesterol or corticosterone treated rats. 
A second group of rats were treated with 50% corticosterone 
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FIG. 2. Comparison of plasma corticosterone (panel A )  and ACTH (panel B )  in morning and evening in sham and 50'h cort pellet treated rats. The 
cort data is shown 6 days following pellet implantation. A flat rhythm of corticosterone is observed by day 6, with a significant increase in plasma 
corticosterone in the a.m. (P=O.O02) and a significant decrease in the p.m. (P=0.04) in 50':0 corticosterone pellet treated rats. The ACTH data 
demonstrate significantly lower plasma ACTH both morning and evening in corticosterone treated rats ( P  =0.006) as well as elimination of the evening 
circadian rise in ACTH in the corticosterone treated rats. *=significantly different from control; XX =significant a.m. YS p.m. difference. EA a.m.; p.m.. 
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TABLE 2. Summary of Data from Repeat 50% Corticosteroiie PeIlet Experiment Plus and Minus Acute Dexamethasone. 
Dexamcthasone 
Cholesterol Corticosteroiie plus 
pellet pellet Dexamethasome corticosterone 
Plasma corticosteronc pg/dl 1.5+1 6.8 k 1.4* 1.0 k0.2 7.8 +2* 
POMC mRNA OD 8 k 1 . 5  4.2*1* 5.8k0.9 3.4*6* 
GR mRNA OD 17.5 & 2.6 18.2+2 17.4k4 6 16.5 1.4 
MR mRNA OD 75.1 k7 .6  72.5 k 3.9 72.8 I .4 12.3 k 12 
CRH mRNA OD 64.5+9 57.5 * 10 36.7 i 8" 24.5+ 12* 
Hippocampus MR binding None detected None detected 
* Significantly different from cholesterol pellet by ANOVA. 
Hippocampus GR binding fmoles/mg protein 85.8 & 8 84.7 & 1 1 58k11* 55+7* 
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FIG. 3 .  Anterior pituitary cell baseline secretion and response to oCRH 
following in vivo treatment with either 50% corticosterone pellets, dexa- 
methasone in the drinking water, or the combination. All 3 treatments 
result in a decrease in baseline ACTH secretion in comparison to placebo 
treated control rats. The percent increase in ACTH secretion following 
oCRH stimulation is similar between control and 50% corticosterone 
treated rats ( 15O'Yo). Dexamethasone treatment appears to inhibit respons- 
iveness to oCRH (127% and 110%) for dex and dex plus cort rats 
respectively). H baseline; + oCRF. 
secretion and responsiveness to oCRH, expressed as percent 
unstimulated secretion ( 127Yn and 110% respectively). 
To determine if the failure of 50% corticosterone pellets to 
produce a decrease in CRH mRNA might occur because corticos- 
terone was too weak an agonist at GR, a comparison of acute 
dexamethasone and acute corticosterone was undertaken. Because 
of the high concentration of corticosterone in this solution 
(200 pg/ml) each rat consumed approximately 1.6 mg of corticos- 
terone. The plasma corticosterone concentration in rats receiving 
corticosterone in the drinking water was elevated to the concentra- 
tion normally seen during the peak of the circadian rhythm in 
the corticosterone treated rats (Table 3) confirming an adequate 
intake of corticosterone (One way ANOVA F=  19.6, P=0.0001; 
P<0.05 Fisher PLSD post-hoc water vs cort). Likewise, the 
plasma corticosterone concentrations in the dexamethasone 
treated rats were suppressed below the very low morning baseline 
(Table 3) although this was not a significant decrease by post-hoc 
testing. Both dexamethasone and corticosterone treated rats 
demonstrated decreased plasma ACTH in comparison to control 
rats (One way ANOVA, F=6.4, P=O.O096; Fisher PLSD post- 
hoc testing dex v s  water P<0.05 and P<0.05 for cort vs water). 
Thymus weight was significantly decreased in dexamethasone 
treated rats (Table 2, P = 0.009). Both acute corticosterone treated 
and acute dexamethasone treated rats demonstrated significant 
decreases in GR binding in hippocampus (ANOVA F =3.5, 
P=0.05; post-hoc Fisher PLSD P<0.05 for dex vs water and for 
cort vs water). The decreases in glucocorticoid binding seen in 
the cortex in dexamethasone and corticosterone treated rats were 
not significant by ANOVA. Both glucocorticoid treatments also 
resulted in decreased CRH mRNA in the PVN (F=5.2, P=0.03 
for treatments; P<0.05 by Fisher PLSD post-hoc testing water vs 
cort and water vs dex). Neither treatment resulted in a significant 
decrease in anterior pituitary POMC mRNA. 
Finally, two additional experiments were undertaken. The first 
was conducted to determine whether implantation of a sham 
pellet may have altered our ability to detect the effects of 50% 
corticosterone treatment. Hippocampal and cortical GR were 
measured in a third group of 50% corticosterone treated rats and 
compared to a group of unhandled control rats. Again, identical 
numbers of GR were seen in unhandled control and 50'% corticos- 
terone treated rats in both hippocampus and cortex. To increase 
the statistical power to detect small decreases in GR, the receptor 
binding data from all 3 studies were combined for statistical 
analysis and still no significant decrease in GR number was 
observed in hippocampus or cortex (Hippocampus Control = 
82.5 & 1 1, Hippocampus Cort = 85.8 & 16; Cortex Control = 
85 & 13, Cortex Cort = 94 f 10). The final experiment evaluated 
whether the lack of effect of 50% corticosterone pellet treatment 
on GR binding was specific to the brain, or also occured in 
peripheral tissues. We examined GR binding in spleen, thymus 
and anterior pituitary. No significant decreases in GR binding 
were seen in any tissue examined, whether central or peripheral. 
Effect of 50% coi*ticostemw pelle fs on stress-induced A CTH 
secretion 
Since the 50% corticosterone pellet rats demonstrated an inhibi- 
tion of diurnal ACTH secretion, the ability of this treatment to 
affect restraint stress induced ACTH secretion in both the a.m. 
and p.m. was explored. In this study, each rat was studied in the 
a.m. and p.m. both before and after 50% corticosterone pellet 
implantation. The plasma ACTH data for 5 and 30 mins of 
restraint stress are shown in Fig. 4. As can be seen, there was a 
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TABLE 3. Effect of Acute Dexamethasone and Acute Corticosterone on Central and Peripheral HPA Axis Markers. 
~ ~~ ~ ~~~~~~~ ~ ~ 
Measure Control Dexamethasone Corticosterone 
Plasma corticosterone (pg/dl) 0.12 k0.05 0.034 & 0.03 1 18.3*4.1* 
Plasma ACTH (pg/ml) 7.1 1 2  2.3 k0.37* (32%) 1.5+0.32* (21%) 
Thymus weight (mg/rat) 685 +43 494 1 40* ( 72'/0) 595 k23 ( 87%)) 
Anterior pituitary POMC mRNA 84.9k8.6 108k7.8 91.5 F3 .4  
Hippocampus GR binding (fmolesjmg protein) 115k24 60*11.5* (52"41) 73k  13* (63%) 
Cortex GR binding (fmoles/mg protein) 74+12 47 & 4 (63%) 50 + I3 ( 67'%1) 
CRH mRNA 54k 1 1  27.5*4.2* (51",L) 29.3*1.1* (54%)) 
* Significantly different from control by ANOVA. 







xx * * *  
. 
a.m. base p.m.base a.m.cort. p.m.cort. " a.m. base p.m. base a.m.cort. p.m.cort. 
FIG. 4. Comparison of ACTH (panel A )  and corticosterone (panel B )  response to a.m. and p.m. restraint in rats before (baseline) and following (pellet) 
implantation of 50% corticosterone pellets. There is no difference in the a.m. vs p.m. ACTH response to restraint stress before 50'% corticosterone pellet 
treatment. Following implantation, a profound inhibition of ACTH secretion is seen in both the a.m. and p.m.. The corticosterone data also demonstrate 
an extremely small adrenal response to this stress following 50% corticosterone pellet treatment. * =significantly different from baseline; XX = significant 
a.m. l:~ p.m. difference. E2 5 min: 30 min. 
clear ACTH response to restraint in both the a.m. and p.m. 
before pellet implantation (baseline). There was no diurnal vari- 
ation in the ACTH response to restraint. Following implantation 
of 50% corticosterone pellets, both the a.m. and p.m. ACTH 
response to restraint was greatly inhibited. There was a significant 
a.m. vs p.m. ACTH response to restraint stress in the corticos- 
terone treated rats (2-way ANOVA, F = 5.4, df = 1, P = 0.03 for 
a.m. vs p.m.). The corticosterone data for the same animals are 
shown in the lower panel. Again, only a very small corticosterone 
response to restraint is seen in either the a.m. or p.m. following 
implantation of the corticosterone pellet. Again, there was a 
significant diurnal difference in the corticosterone response to 
restraint in both the baseline and corticosterone treated groups 
('-way ANOVA, F=8.0, df=1, P=0.009 for a.m. vsp.m.). 
Discussion 
The data presented here describe two different doses of chronic 
corticosterone that lead to different plasma corticosterone profiles 
and different adaptations on the part of the HPA axis. The 25%) 
corticosterone pellets resulted in an increase in the morning 
corticosterone but preservation of the circadian rhythm of cortico- 
sterone while 50% corticosterone pellets produced an inhibition 
of the normal evening rise in plasma corticosterone, suggesting a 
flat circadian rhythm of corticosterone, although a shift in timing 
of the peak cannot be excluded with only two time points of 
sampling. In both the 25'% and 50'% pellet experiments, the 
cholesterol pellet controls rats demonstrated morning corticos- 
terone concentrations of 1.5 pg/dl; the 25% pellet rats demon- 
strated morning corticosterone concentrations of 3.4 pg/dl, while 
the 50% corticosterone pellet rats demonstrated morning corticos- 
terone concentrations of 5.6pg/dl. The small increase in a.m. 
plasma corticosterone in the 25% corticosterone pellet rats did 
not lead to any change in the evening plasma ACTH or corticos- 
terone secretion, while the additional increment in plasma cortico- 
sterone in the 50'% corticosterone pellet rats led to a significant 
suppression of a.m. plasma ACTH concentrations, and a suppres- 
sion of the diurnal rhythm of ACTH and corticosterone secretion. 
The 25% pellets did not lead to a significant decrease in thymus 
weight or adrenal weight. Similarly, there were no changes 
anterior pituitary ACTH content nor in POMC mRNA levels. 
These data suggest that the HPA axis was able to adapt to the 
small increase in morning corticosterone with few, if any, con- 
sequences. This was in clear contrast to the effects of 50% pellet 
administration, which led to a significant decrease in both thymus 
weight, and adrenal weight as well as a decrease in anterior 
pituitary POMC mRNA levels and the suppression of the evening 
circadian peak of ACTH and corticosterone secretion. However, 
even the 50"/0 corticosterone pellet treatment did not lead to a 
decrease in ACTH anterior pituitary content. In the 50% corticos- 
terone pellet treated rats, both release, as reflected by plasma 
ACTH concentrations, and biosynthesis, as reflected by POMC 
mRNA levels, were decreased in parallel, which could explain the 
lack of change in ACTH stores. This suggests that steady state 
hormone stores are not the best indication of the activity of an 
endocrine gland. 
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In contrast to the clear indication of increased corticosterone 
concentrations in the peripheral measures of HPA axis function, 
there was no indication that either 25Yn or 50% corticosterone 
pellets produced any decrease in available G R  (occupation or 
down-regulation) in hippocampus, cortex. hypothalamus, spleen 
or thymus. In second experiment G R  and M R  mRNAs in the 
hippocampus were measured and there was no indication that 
the chronic cort treatment produced receptor down-regulation at 
the mRNA level. This suggests that relatively high concentrations 
of circulating glucocorticoids may be necessary to produce signi- 
ficant occupation of Type I1 receptors, and that the corticosterone 
pellets never achieved this concentration. This hypothesis is 
supported by the data of Spencer ef al. (18) examining G R  and 
MR occupation in intact rats during the peak and nadir of the 
circadian rhythm. as well as data from Reul et a1 examining the 
effects of acute stress on M R  and G R  occupation (21, 22). In 
adrenally intact rats the increase in corticosterone from to 20 pgdl 
in the evening from 1 pgdl in the a.m. resulted in a 25% decrease 
in G R  in the hippocampus and cortex. Given that the increases 
in plasma corticosterone concentrations resulting from the 5 0 %  
corticosterone pellets was only 25% of the normal diurnal change, 
a decrease of only 6'%, may be far too small to  produce a detectable 
signal. Alternatively, the changes induced by chronic glucocort- 
icoid treatment may be compensated by changes in the biosyn- 
thesis, half-life or distribution of receptors, so that available 
cytosolic receptors d o  not appear to produce meaningful informa- 
tion following chronic treatment. Finally, the inability to  detect 
decreases in G R  and MR mRNA levels in whole hippocampus 
may reflect regional specific regulation of these mRNAs in 
hippocampal subfield. as already been reported for adrenalectomy 
induced increases (23). Despite our inability to  demonstrate any 
effects of corticosterone pellet treatment on G R ,  the small increase 
in glucocorticoids with this treatment resulted in inhibition of 
anterior pituitary POMC mRNA levels and inhibition of plasma 
ACTH secretion in both the a.m. and p.m.. 
In the Spencer et al. study (18), a small number of M R  could 
be detected in adrenally intact rats in the a.m. but not the p,m. 
In these current studies, M R  could not be detected in any groups 
of rats, even the control rats with plasma corticosterone concen- 
trations of 1.5 pg/dl or lower. This suggests either that these 
receptors are present in extremely small numbers in intact rats of 
this strain, or that these low levels of corticosterone are capable 
of fully occupying these receptors (21). In neither dexamethasone 
experiment could we detect M R  binding in the dexamethasone 
treated groups. This is rather surprising since Spencer et al. (15)  
demonstrated that this same dose of dexamethasone was able to 
lead to an increase in M R  signal in non-adrenalectomized rats. 
Since the data of that group suggest that higher doses of dexa- 
methasone in the drinking water will decrease M R  binding, it 
may be that in the studies of Spencer et al. (15), the rats consumed 
less dexamethasone than in either of these two experiments. 
Because occupied MR in the nucleus cannot rebind steroid 
hormones in exchange assays ( 1  5 ) ,  we cannot determine if the 
failure to detect these receptors in cytoplasm results from only a 
small total pool of receptors or whether the majority of receptors 
are occupied and translocated to  the nucleus. It should be noted 
that the studies of Reul et al. (22, 24, 25) found that the acute 
injection of dexamethasone produced no increase in M R  binding 
for a full 24 h, even though the injection blocked the evening rise 
in corticosterone. Chronic dosing of corticosterone produced an 
increase in M R  binding as well as a decrease in G R  binding. 
Although GR and M R  mRNA levels may be helpful in determin- 
ing whether receptor down-regulation has occurred, our previous 
studies found no change in M R  or  G R  mRNA levels in response 
to injection of corticosterone in sesame oil, a paradigm (20) a 
paradigm previously demonstrated to  produce glucocorticoid 
receptor down-regulation (26). However. it is possible that 
regional changes in G R  or M R  mRNA levels in hippocampal 
subfields may occur as has been demonstrated for adrenalectomy 
(23). Finally, steady state mRNA levels d o  not always reflect 
changes occuring at the level of transcription and translation. 
Chronic corticosterone treatment had no effect on CRH mRNA 
levels in the PVN, while acute dexamethasone administration did. 
Since dexamethasone is a synthetic steroid with a higher affinity 
for G R  than corticosterone, it was possible that corticosterone is 
too weak of a G R  agonist to affect binding and CRH mRNA. 
To test this hypothesis, we administered a high dose of corticos- 
terone overnight in the drinking water similar to that given by 
Miller and colleagues (, 17). These experiments were designed to 
demonstrate that a higher plasma corticosterone concentration 
(18 pgldl) was capable of affecting the central measures of 
glucocorticoid inhibition, since these effects were not seen with 
50%) corticosterone pellets (5-6 pg/dl ). The plasma concentration 
of corticosterone achieved by this paradigm is similar to the 
plasma concentration during the circadian peak of corticosterone 
secretion. In the acute dexamethasone and acute corticosterone 
experiment, both steroids demonstrated clear inhibitory effects 
on basal ACTH secretion, even though the morning is normally 
the time of the trough in ACTH secretion in rats. Neither 
treatment led to a decrease in anterior pituitary POMC mRNA, 
probably because 12 h is too short of a time to  lead to significant 
decreases in a large pool of mRNA. Both acute treatments were 
able to decrease C R H  mRNA in the PVN; the decrease seen with 
dexamethasone treatment was similar in both experiments (50%1 
of control). Finally, the comparisons between acute and chronic 
treatments involve both differences in absolute doses of steroids 
and differences in plasma corticosterone levels as well as differ- 
ences in time course, so it is not possible to ascribe differences in 
HPA axis profiles produced by these different treatments to  time 
course or dose alone 
The 50% corticosterone pellet treated rats demonstrated clear 
inhibition of HPA axis but the sites of this inhibition are less 
clear. Corticosterone treatment blocks the normal evening rise of 
corticosterone, suggesting a t  least a pituitary site of inhibition. 
The decrease in POMC mRNA further supports inhibitory effects 
a t  the pituitary. The decrease in baseline ACTH secretion and 
decreased ACTH response to 1nM C R F  in 50% corticosterone 
pellet treated rats suggest that the pituitary is an important 
site of the negative feedback on ACTH secretion. particularly 
by decreasing readily releasable stores of ACTH. The similar 
response to oCRF. expressed as percent baseline, between anterior 
pituitaries from cholesterol treated and corticosterone treated rats 
suggest that the changes d o  not involve changes in pituitary C R F  
receptors. Despite a clear decrease in POMC mRNA, there were 
no changes in CRH mRNA in the PVN in the 50%) corticosterone 
treated animals. Both CRH and vasopressin in the parvocellular 
division of the PVN are known to be secretagogues in the HPA 
axis. The current studies do not address vasopressin mRNA levels 
in the PVN because there are a large number of magnocellular 
vasopressin neurons within the micropunch area and these magno- 
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experiments examined these same measures on day 6 in the a.m. In the 
repeat 50% corticosterone pellet experiment. a total of 12 rats received 
corticosterone pellets and 12 rats received cholesterol pellets. Five days 
following the implantation of the pellets, half of each group was 
given dexamethasone 1.5 pg/ml overnight in their drinking water (water 
was changed at 16.00). The other half of the rats were given normal 
drinking water. 
All rats were sacrificed the following morning. A repeat experiment for 
acute dexamethasone consisted of overnight dexamethasone administra- 
tion in the drinking water (1.5 pg/ml) to 6 rats, overnight corticosterone 
administration in the drinking water (200 pg/ml) to 6 rats and normal 
drinking water in the control rats. All rats were sacrificed the following 
morning. A repeat experiment consisted of overnight dexamethasone 
administration in the drinking water (1.5 pg/ml) to 6 rats, overnight 
corticosterone administration in the drinking water (200 pg/ml ) to 6 rats 
and normal drinking water in the control rats. Again, all rats were 
sacrificed the following morning and all hormone measures are from 
those time points. 
In vivo experiments examining a.m. and p.m. stress responsiveness 
utilized a repeated measure design. Each animal was exposed to 30 min 
of a.m. and p.m. restraint (separated by 3 days) before implantation of 
the 50Y0 corticosterone pellets. Blood for ACTH and corticosterone was 
obtained by tail nick into non-heparinized capillary tubes. Following the 
time 0 sample (corticosterone only), a drop of dilute heparin-saline 
(1000 u/ml) was placed over the cut. The 5 and 30 min samples were 
collected from the same nick. Immediately following filling of each 
capillary tube, the sample was transferred from the capillary tube into an 
EDTA solution to prevent clotting. 
Tissue processing 
Trunk blood was collected in K+EDTA containing tubes on ice, centri- 
fuged immediately, the plasma separated and acidified with IN HCl, then 
frozen on dry ice. It was subsequently stored at -70°C until extraction. 
Brains were removed from the skull, dissected on ice into the following 
regions: hippocampus, cortex overlying the hippocampus, and hypothal- 
amus. These regions were frozen immediately on dry ice and stored at 
-70°C until the day of assay. To avoid contamination of the anterior 
lobe of the pituitary by intermediate lobe melanotrophs, the neurointerme- 
diate lobe of the pituitary was removed from the anterior lobe, and the 
portions of the anterior lobe contacting the intermediate lobe was 
discarded. The anterior lobe fragments were then frozen on dry ice and 
stored at -70°C until extraction. For anterior pituitary in vitro challenge 
studies, anterior pituitaries from 3 animals were pooled, processed into 
single cell suspensions using collagenase treatment, and challenged with 
oCRF using the methods previously described (29). Aliquots of the single 
cell suspension containing 250,000 cells were incubated with either medium 
alone or 1 nM oCRF for 60 min at 37°C under 950/00,, 5"/oco,. All 
samples were run in triplicate. At the end of the hour, the cell suspensions 
were centrifuged, the media collected for assay, and the the cells were 
extracted with GITC extraction described below. Thymuses were collected 
into 24 well microtiter plates with a small amount of isotonic saline, 
blotted on weighing paper, then weighed on the same day as the 
experiment. Adrenals were treated similarly; the outer capsulc and fat 
was removed before weighing. 
Hormonal assays 
Plasma samples were extracted with Sep-Pak C,, cartridges using our 
previously described procedure (30). Samples were assayed for corticos- 
terone using an RIA with our own antibody to corticosterone. This RIA 
is very specific for corticosterone and cross-reacts less than 2% with 
cortisol or 1 1-deoxycorticosterone. The assay buffer is 50 mM sodium 
phosphate containing 2.5% bovine serum albumin, pH 7.5. Following 
extraction the samples are re-suspended in assay buffer and two dilutions, 
the equivalent of 2 p1 and 5 pl of plasma are compared to determine 
which reads in the linear range of the curve. [3H] corticosterone was used 
as the radiolabeled ligand. Bound and free were separated by the addition 
of a charcoakdextran mixture (1% : O.l'!h) and centrifugation at 3000 x g. 
The assay sensitivity is 0.5 pgldl. Samples were assayed for ACTH by 2 
methods, an RIA using our own antibody raised to ACTH 11-24. and 
the Allegro HS ACTH kit (Nichols Institute, San Juan Capistrano, CA. 
USA). Because the ACTH samples were extracted, 25 pl aliquots con- 
taining the equivalent of 250 p1 of plasma that were resuspended in 0.1% 
HSA were diluted to 200 p1 using the equine serum zero standard provided 
cellular neurons are not sensitive to glucocorticoid regulation 
(27). Thus it is possible that changes in vasopressin mRNA levels 
occur within the parvocellular division in our 50% corticosterone 
treated rats. Given the clear inhibition of the HPA axis, including 
both circadian and stress induced ACTH secretion, the decrease 
in ACTH secretion from anterior pituitary in vitro, and the 
decrease in anterior pituitary POMC mRNA levels resulting from 
50% corticosterone pellet treatment, the pituitary as a site of 
inhibition has some experimental support. 
Recent studies by Akana et al. (28 )  used a similar corticosterone 
pellet regimen of 20%, 40% and 80% corticosterone pellets. They 
observed with the 20% and 40% corticosterone pellets results that 
are comparable to our results with 25% and 50% corticosterone 
pellets on thymus weight, adrenal weight and peripheral plasma 
corticosterone concentrations, including the suppression of the 
circadian rhythm of corticosterone in the 40% corticosterone 
treated animals but not in the 20% corticosterone treated animals. 
They also observed a decreased ACTH and corticosterone 
response to restraint stress in the a.m. with 40% corticosterone 
pellet treatment. The same stress repeated in the p.m. resulted in 
an inhibition of the ACTH stress response only in the 80% 
corticosterone pellet group, demonstrating an a.m./p.m. difference 
in the effectiveness of the 40% corticosterone pellets in inhibiting 
HPA axis activation by stress. Our data with 50% corticosterone 
pellets demonstrate clear inhibition of the stress response in both 
the a.m. and p.m.. Differences between our data and their data 
probably result from higher plasma corticosterone levels (average 
6.2 pg/dl) in the 50% corticosterone treated rats compared to 
their 40% corticosterone treated rats (4.0 pg/dl). 
In conclusion, exogenous 50% corticosterone pellets caused 
profound inhibition of the HPA axis, but did lead to no detectable 
occupation of GR in the hippocampus, cortex, thymus or spleen. 
Thus it appears that examining the number of available cytosolic 
glucocorticoid receptors was not informative in this paradigm, 
probably because of the long term nature of the treatment. Given 
the data suggesting clear inhibition of the stress response in vivo, 
and inhibition of the anterior pituitary secretion in vitro, both 
pituitary and brain appear to be likely sites of the inhibitory 
effects of this treatment. 
Methods 
All studies were approved by the university committee on the use and 
care of animals. All studies were conducted on male Sprague Dawley rats 
obtained from Charles River (Portage, MI, USA), weighing 150-200 gs 
at the time of their arrival. All rats were given a minimum of one week 
to adapt to the stress of shipment before any experimental manipulations 
were initiated. All rats were maintained on a 12 h light/dark schedule and 
were given food and water ud libitum. All animals were group housed 
(6/cage) for these experiments. Rats sacrificed in the morning were within 
3 h of 'lights on' and those in the evening within 2 h of 'lights of f ' ,  but 
always during the lights on period. Exogenous corticosterone was adminis- 
tered as a 100 mg corticosterone/cholesterol pellet implanted subcutane- 
ously under metofane anesthesia as described by Dallman et a/. (2). 
Experimental Design 
These experiments involved the implantation of either 25% or 50'% 
corticosterone/cholesterol pellets (100 mg total) in the experimental 
group, and cholesterol pellets (100 mg) in the control animals on day 0. 
Animals were sacrificed at 2 times, day 6 in the morning and evening. 
Each group consisted of 6 rats. At each time trunk blood and pituitaries 
were collected for hormonal assays, brains for glucocorticoid receptor 
assays and adrenals and thymuses for weight determination. Subsequent 
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by the kit. p-endorphin was assayed using the previously described assay 
(24, 25). This antibody recognizes fully both 0-lipotropin and 
P-endorphin. and thus gives a reliable index of corticotrope secretion. 
Anterior pituitaries were extracted using a guanidium-isothiocyanate 
(GITC) extraction. Tissue were homogenized through a 26 Ga needle in 
300p1 of GT buffer (guadinium isothiocyanate (5M), 10mM EDTA, 
50 mM Tris, 8% mercaptoethanol). Five volumes of 4M LiCl were added 
and the samples were precipitated overnight at 4°C. Following centrifu- 
gation. the supernatant containing proteins was further extracted by Sep- 
Pak extraction, lyophilized and then assayed for ACTH using the radio- 
immunoassay previously described. (25) This assay utilizes an antibody 
raised to ACTH 11-24. which recognizes ACTH and larger molecular 
weight forms (22K and POMC) but not alpha-MSH. The pellet containing 
nucleic acids was digested with 300 pI of proteinase K (150 pg/ml) 
solution. and then mRNA was precipitated in ethanol at -20°C for 
subsequent POMC mRNA quantitation. Approximately 3 pg of total 
RNA was loaded on a I % ~ g ~ ~ o s e ~ o ~ ~ ~ l d e ~ y d e ~ e l  an  lectmphoreseded 
for 6-8 h, then blotted onto Nytran membrane (0.45 pM) overnight. 
Membranes were probed with a 32P labeled cRNA probe transcribed 
from a full length rat POMC cDNA (960 bp. Eberwine) and apposed to 
autoradiographic film. Appropriate size bands on the X-ray film were 
quantitated by optical density and normalized to total ribosomal RNA, 
as determined by an 35S labeled ribosomal RNA probe of the same 
membrane. or normalized to PI B15 mRNA (corticosterone injection 
experiments), 
A 2 rnm section through the hypothalamus containing the paraventricu- 
lar nucleus (PVN) was dissected using a brain block slice with subsequent 
removal of tissue lateral to the PVN. The hippocampus and frontal cortex 
were dissected from the region caudal to the hypothalamic slice. All tissue 
was frozen immediately on dry ice and stored at  ~ 80°C until subsequent 
extraction. The RNA was extracted from the anterior pituitary, paired 
PVN, and one hippocampus from each animal using a guanidium 
isothiocyanate extraction (GITC). Tissues were homogenized in buffer 
containing 5M GITC, 10mM EDTA, 50mM Tris HC1 (pH 7.5), 8% 
(v/v) P-mercaptoethanol, then precipitated with 5 volumes of 4M LiCl at 
4°C. The precipitates were pelleted by centrifugation and treated with 
proteinase K (lOOpg/ml in 0.5% SDS, 50mM Tris HC1) for 1-2h at 
37'C. The samples were extracted by phenol-chloroform then precipitated 
in EtOH. Following EtOH precipitation, RNA samples from the PVN 
and the hippocampus were used in a RNAse protection assay as previously 
described (19). Briefly, A 751 bp fragment of the rat CRF cDNA 
(provided by A. Seasholtz) was transcribed to yield a cRNA probe labeled 
with 3ZP-UTP. The rat glucocorticoid receptor clone spanning 450 bp of 
the 3' untranslated Ranking sequence was used as a template for cRNA 
synthesis. The rat mineralocorticoid receptor DNA was a 550 bp fragment 
of the 3' translated and untranslated region. These probes were added to 
the respective hybridization mix (400 mM PIPES pH 6.4, 0.4 M NaCl. 
1 mM EDTA. 50% formamide) containing 1/3 of the RNA extracted 
from paired PVN from each rat, or from one hippocampus of each rat. 
Hybridization takes place for 14-16 h at 55°C. RNAse A, 10 pg/ml was 
added and incubated for 15-30 min at room temperature. RNAse is 
neutralized by addition of 1% SDS and proteinase K for 30 min at  37°C. 
The samples were then precipitated in EtOH, resuspended in 20% 
formamide and separated on a 4%) polyacrylamide gel. The gel was 
apposed to X-ray film (Kodak X-ar) and resulting bands quantified by 
densitometry. 
Glucocortiroid receptor assays 
For measurement of GR in brain, single point assays on one hippocampus 
and one cortex of each animal were performed using a saturating 
concentration of ligand ( 10 nM [3H]-dexamethasone) to quantitate bind- 
ing for each animal (17, 18, 30). 500 nM RU 26988, a specific Type I1 
(GR) agonist, was used to determine GR binding and 2.5 pM corticos- 
terone was used to determine non-specific binding. The other hippocampus 
and cortex from each animal of the same group were pooled for Scatchard 
plot binding data (experiment 1 only). For hypothalamus, single point 
assays alone were performed. For the actual binding assay, frozen regions 
were homogenized with 15 strokes in a hand held glass homogenizer in 
lOmM ice cold Tris buffer, pH 7.4, with 1 mM EDTA, 10% glycerol, 
20 mM molybdate. and 1 mM dithiothreitol. The homogenate was centri- 
fuged at 40,000 rpm in an ultracentrifuge with T 1-50 rotor for 30 min. 
then the cytosol (supernatant) was transferred with pasteur pipette to a 
glass test tube and remained on ice until addition of labeling ligand. For 
Scatchard plot analyses, an aliquot of the cytosol (100 pl) was incubated 
with increasing concentrations of [3H] dexamethasone (0.1-10 nM) with 
and without 500nM RU 26988 (a specific Type I1 antagonist). Excess 
(2.5 p M )  corticosterone was used to determine specific total binding (MR 
plus GR). The samples plus radiolabelled ligand are incubated overnight 
at 0°C then bound [3H] ligand is separated from free by use of LH-20 
minicolumns (25% corticosterone pellet) or dextran coated charcoal (other 
experiments). The eluate from the minicolumn, which contains bound 
receptor-ligand complex, is collected directly into scintillation vials. 
scintillation cocktail is added and the samples are counted. Alternatively, 
following the addition of dextran coated charcoal, the incubation tubes 
were centrifuged, and the supernatant, containing bound receptor-ligand 
complex, was aliquotted into scintillation vials. and scintillation cocktail 
was added. All samples were run in triplicate, the triplicates were averaged, 
and fmoles bound were calculated. A small sample of the original cytosol 
was assayed for protein content with Bio Rad protein assay; the binding 
values are expressed as fmoles bound/mg protein. 
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